45
Participants
Start Date
March 28, 2024
Primary Completion Date
May 5, 2024
Study Completion Date
August 10, 2024
hyaluronidase
150 IU group D1:150 IU hyaluronidase+500 ml Lactated Ringer's (LR)(Subject's left or right leg); D2:150 IU hyaluronidase+250 ml Lactated Ringe's (LR)(Subject's left or right arm); D3:150 IU hyaluronidase+500 ml Normal Saline (NS)(subject's left or right leg); D4:150 IU hyaluronidase+1000 ml Lactated Ringer's (LR)(Subject's back); 385 IU group D1:385 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm); 1500 IU group D1:1500 IU hyaluronidase+250 ml Lactated Ringer's (LR)(Subject's left or right arm).
Placebo
150 IU group D1:Placebo+500 ml Lactated Ringer's (LR)(Subject's left or right leg); D2:Placeboe+250 ml Lactated Ringer's (LR)(Subject's left or right arm); D3:Placebo+500 ml Normal Saline (NS)(Subject's left or right leg); 385 IU group D1:Placebo+250 ml Lactated Ringer's (LR)(Subject's left or right arm); 1500 IU group D1:Placebo+250 ml Lactated Ringe's (LR)(Subject's left or right arm).
Suzhou Municipal Hospital, Suzhou
Shanghai Bao Pharmaceuticals Co., Ltd.
INDUSTRY